Home Tags CD30

Tag: CD30

General Views during at the American Society of Hematology 61th Annual Meeting at the Orange County Convention Center. Photo courtesey 2019 © ASH/Danny Morton.

ASH 2019: Brentuximab Vedotin + Nivolumab in Frontline and R/R Hodgkin...

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris®; Seattle Genetics/Takeda) and nivolumab (Opdivo®; Bristol‑Myers Squibb) in frontline Hodgkin lymphoma...
Featured Image: American Society of Hematology | Annual Meeting. Courtesy: © 2017. American Society of Hematology. Used with permission.

What to Expect at ASH 2019: Seattle Genetics

With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the presentations to look for.This year...
Featured Image: Journal + glasses. Courtesy: © 2017 - 2019. Fotolia. Used with permission.

The Lancet Publishes Positive Phase III Trial Data of Brentuximab Vedotin...

Data from the randomized Phase III ALCANZA clinical trial evaluating brentuximab vedotin (Adcetris®)  in patients with cutaneous T-cell lymphoma (CTCL) were published in the...
Guell park in Barcelona

Anna Sureda MD PhD: “An Intelligent Way to Deliver High Doses...

Surrounded by fantastical and modernist landmarks designed by Antoni Gaudí, Barcelona, in the northeast of Spain, is a surreal wonderland where mansions look like...

Breakthrough Therapy Designation for Brentuximab Vedotin in CD30-expressing Mycosis Fungoides and...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of patients with...

Phase II Trial Evaluates Brentuximab Vedotin in Systemic Lupus Erythematosus

A new phase II clinical trial designed to evaluate the safety and efficacy of brentuximab vedotin (Adcetris®; Seattle Genetics) in systemic lupus erythematosus also known...

Brentuximab Vedotin Data from the AETHERA Post-Transplant Consolidation Setting Presented at...

Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...

Supplemental BLA for Brentuximab Vedotin in Post-Transplant Hodgkin Lymphoma Patients at...

Based on positive data from the Phase III AETHERA trial (SGN35-005; NCT01100502) of brentuximab vedotin (Adcetris®; Seattle Genetics, Inc/Takeda Oncology) as consolidation therapy immediately following...

Brentuximab Vedotin Shows 42% Objective Response Rate in Patients with Relapsed...

New, updated, data from a phase II clinical trial of brentuximab vedotin (Adcetris®; Seattle Genetics) in patients with diffuse large B-cell lymphoma or DLBCL and other B-cell non-Hodgkin lymphomas, demonstrated an encouraging activity and tolerability profile in the relapsed and refractory setting. The results were presented at the 55th annual meeting of ASH®, the American Society of Hematology, held in New Orleans, Louisiana, USA, from December 7 - 10, 2013.

Phase III Front-line Trial Planned with Brentuximab Vedotin in Advanced Stage...

Interim results from a phase I clinical trial of brentuximab vedotin(SGN-35, Adcetris™, Seattle Genetics/Millennium: The Takeda Oncology Company) in combination with chemotherapy for the...